Clinical Trial Update: Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Heat Shock Protein-Peptide Complex-96 (HSPPC-96) to IL-2 plus dacarbazine in Stage IV malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• HSPPC-96 (heat shock protein peptide complex-96)
• IL-2 + DTIC (interleukin-2; dacarbazine)

Snippet

Sponsor: Agenus Inc. | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED